Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone

Author:

Mahdal Michal12ORCID,Tomáš Tomáš12,Apostolopoulos Vasileios12ORCID,Adámková Dagmar23,Múdry Peter24ORCID,Staniczková Zambo Iva25ORCID,Pazourek Lukáš12ORCID

Affiliation:

1. First Department of Orthopaedic Surgery, St. Anne’s University Hospital, 60200 Brno, Czech Republic

2. Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic

3. Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 60200 Brno, Czech Republic

4. Department of Pediatric Oncology, University Hospital Brno, 66263 Brno, Czech Republic

5. First Department of Pathology, St. Anne’s University Hospital, 60200 Brno, Czech Republic

Abstract

Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15–79). The follow-up period was 8.32 years (2–16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19–11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09–9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: −4.00 [95% CI: –6.81 to −1.18]; p < 0.001 and mean difference: −5.36 [95% CI: −3.74 to −6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection.

Funder

Ministry of Healthcare of the Czech Republic

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference42 articles.

1. Giant-Cell Tumor of Bone;Campanacci;J. Bone Jt. Surg. Am.,1987

2. Giant Cell Tumour of Bone;Thomas;Curr. Opin. Oncol.,2009

3. The Clinical Approach Toward Giant Cell Tumor of Bone;Dijkstra;Oncologist,2014

4. Giant Cell Tumor of Bone: Treatment and Outcome of 214 Cases;Balke;J. Cancer Res. Clin. Oncol.,2008

5. Giant Cell Tumor of the Extremity: A Review of 349 Cases from a Single Institution;Errani;Cancer Treat. Rev.,2010

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3